- Home
- MUR vs TGTX Comparison
MUR vs TGTX Comparison
Compare MUR & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MUR
- TGTX
- Stock Information
- Founded
- MUR 1950
- TGTX 1993
- Country
- MUR United States
- TGTX United States
- Employees
- MUR N/A
- TGTX N/A
- Industry
- MUR Oil & Gas Production
- TGTX Biotechnology: Pharmaceutical Preparations
- Sector
- MUR Energy
- TGTX Health Care
- Exchange
- MUR Nasdaq
- TGTX Nasdaq
- Market Cap
- MUR 4.7B
- TGTX 5.4B
- IPO Year
- MUR N/A
- TGTX 1995
- Fundamental
- Price
- MUR $28.22
- TGTX $32.20
- Analyst Decision
- MUR Hold
- TGTX Strong Buy
- Analyst Count
- MUR 13
- TGTX 6
- Target Price
- MUR $39.58
- TGTX $40.67
- AVG Volume (30 Days)
- MUR 1.8M
- TGTX 2.2M
- Earning Date
- MUR 01-23-2025
- TGTX 11-04-2024
- Dividend Yield
- MUR 4.25%
- TGTX N/A
- EPS Growth
- MUR N/A
- TGTX N/A
- EPS
- MUR 3.09
- TGTX N/A
- Revenue
- MUR $3,191,294,000.00
- TGTX $264,790,000.00
- Revenue This Year
- MUR N/A
- TGTX $43.74
- Revenue Next Year
- MUR $1.08
- TGTX $64.30
- P/E Ratio
- MUR $9.09
- TGTX N/A
- Revenue Growth
- MUR N/A
- TGTX 39.53
- 52 Week Low
- MUR $27.75
- TGTX $12.84
- 52 Week High
- MUR $49.14
- TGTX $36.84
- Technical
- Relative Strength Index (RSI)
- MUR 26.56
- TGTX 51.73
- Support Level
- MUR $29.97
- TGTX $30.41
- Resistance Level
- MUR $29.56
- TGTX $35.03
- Average True Range (ATR)
- MUR 0.84
- TGTX 1.80
- MACD
- MUR -0.28
- TGTX -0.46
- Stochastic Oscillator
- MUR 9.15
- TGTX 35.31
About MUR Murphy Oil Corporation
Murphy Oil is an oil and gas exploration and production company, with both onshore and offshore operations and properties. It operates in two geographic reportable segments the United States and Canada. It generates the majority of its revenue form the United States.
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.